Sam Brusco05.07.21
Life Spine won a second ruling barring Aegis Spine from marketing, selling, or distributing its AccelFix-XT devices.
A preliminary injunction preventing Aegis’s marketing and sale of its AccelFix-XT line of expandable medical devices has been in effect since April 5. Aegis’s attempt to stay the injunction was denied on May 4.
The United States District Court for the Northern District of Illinois issued the injunction after finding Aegis and parent company, L&K Biomed Co., Ltd., used Life Spine’s proprietary PROLIFT expandable cage to develop the AccelFix-XT.
In response to Aegis’ motion to stay the injunction pending its appeal to the Seventh Circuit, the Court reaffirmed its finding that “Life Spine has a high likelihood of success on its [various] claims based on evidence that, among other things, Aegis took calculated steps to help copy or reverse engineer the PROLIFT implant, disclosed Life Spine’s confidential information to third parties, shipped the PROLIFT implant to a third party without Life Spine’s knowledge or permission, and failed to train its employees regarding its contractual confidentiality obligations.”
Given the Court’s wholesale rejection of Aegis’s arguments, the injunction preventing Aegis’s marketing and sale of any items in the AccelFix-XT product line remains.
Life Spine’s CEO Michael Butler told the press: “The Court’s ruling validates our claims and we appreciate the thorough analysis of the issues presented. The ruling protects the propriety technology around our PROLIFT Expandable Implants.”
A preliminary injunction preventing Aegis’s marketing and sale of its AccelFix-XT line of expandable medical devices has been in effect since April 5. Aegis’s attempt to stay the injunction was denied on May 4.
The United States District Court for the Northern District of Illinois issued the injunction after finding Aegis and parent company, L&K Biomed Co., Ltd., used Life Spine’s proprietary PROLIFT expandable cage to develop the AccelFix-XT.
In response to Aegis’ motion to stay the injunction pending its appeal to the Seventh Circuit, the Court reaffirmed its finding that “Life Spine has a high likelihood of success on its [various] claims based on evidence that, among other things, Aegis took calculated steps to help copy or reverse engineer the PROLIFT implant, disclosed Life Spine’s confidential information to third parties, shipped the PROLIFT implant to a third party without Life Spine’s knowledge or permission, and failed to train its employees regarding its contractual confidentiality obligations.”
Given the Court’s wholesale rejection of Aegis’s arguments, the injunction preventing Aegis’s marketing and sale of any items in the AccelFix-XT product line remains.
Life Spine’s CEO Michael Butler told the press: “The Court’s ruling validates our claims and we appreciate the thorough analysis of the issues presented. The ruling protects the propriety technology around our PROLIFT Expandable Implants.”